Presenting

By the end of the review, attendees will be better equipped to:

• Determine which patients with hematologic malignancy may benefit from specific targeted therapy

• Recognize myriad of presentations of patients with hematologic illnesses

• Identify higher-risk patients with hematologic malignancy and determine the best available therapies

• Prescribe individualized plans for patients with hematologic malignancies based on specific disease characteristics (genetics, molecular markers, etc.)

• Manage complications of hematologic malignancies in an outpatient setting

• Familiarize health care practitioners with the latest updates as per clinical trial data in the proper diagnosis and treatment of benign hematologic diseases, such as sickle cell anemia, coagulopathies, and autoimmune hemolytic anemias